Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00192452 | Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis | PHASE2 | COMPLETED | 120 | — | — | Mar 1, 2001 | Dec 1, 2001 | Oct 25, 2006 | 3 | United States |
| Name | Type | Description |
|---|---|---|
| MEDI-507 | DRUG | - |
Inclusion Criteria: * Plaque psoriasis involving at least 10% of body surface area (Appendix B) * Age 18 through 65 years at the time of the first dose of study drug * Both males and females are eligible. However, sexually active females, unless surgically sterile or at least 1 year post-menopausal...